Q1 Earnings Estimate for Liquidia Issued By Lifesci Capital

Liquidia Co. (NASDAQ:LQDA) – Equities research analysts at Lifesci Capital issued their Q1 2025 earnings estimates for Liquidia in a research note issued to investors on Wednesday, March 19th. Lifesci Capital analyst C. Jubinville expects that the company will post earnings of ($0.37) per share for the quarter. The consensus estimate for Liquidia’s current full-year earnings is ($1.51) per share.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). The company had revenue of $2.92 million for the quarter, compared to analysts’ expectations of $4.60 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%.

A number of other analysts also recently commented on the stock. Needham & Company LLC boosted their price objective on shares of Liquidia from $19.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday. HC Wainwright reissued a “buy” rating and set a $29.00 price objective on shares of Liquidia in a report on Thursday. Wells Fargo & Company initiated coverage on shares of Liquidia in a report on Friday, December 20th. They set an “overweight” rating and a $20.00 price objective on the stock. Finally, Scotiabank upped their price target on shares of Liquidia from $30.00 to $34.00 and gave the company a “sector outperform” rating in a report on Thursday. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $26.63.

Liquidia Trading Down 2.1 %

LQDA stock opened at $15.12 on Friday. The company has a market cap of $1.28 billion, a P/E ratio of -9.28 and a beta of 0.07. Liquidia has a 52 week low of $8.26 and a 52 week high of $16.99. The company’s 50-day moving average price is $14.79 and its 200 day moving average price is $12.18.

Insider Buying and Selling at Liquidia

In related news, CFO Michael Kaseta sold 23,370 shares of the company’s stock in a transaction that occurred on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $275,298.60. Following the transaction, the chief financial officer now owns 401,755 shares of the company’s stock, valued at approximately $4,732,673.90. This represents a 5.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Rajeev Saggar sold 6,249 shares of the company’s stock in a transaction that occurred on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $73,613.22. Following the transaction, the insider now directly owns 270,388 shares in the company, valued at $3,185,170.64. The trade was a 2.26 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 71,245 shares of company stock valued at $843,326 over the last quarter. Corporate insiders own 30.10% of the company’s stock.

Hedge Funds Weigh In On Liquidia

Institutional investors and hedge funds have recently modified their holdings of the company. Steward Partners Investment Advisory LLC purchased a new position in shares of Liquidia during the fourth quarter valued at approximately $59,000. Summit Investment Advisors Inc. lifted its stake in shares of Liquidia by 35.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company’s stock valued at $78,000 after buying an additional 1,719 shares during the period. Walleye Trading LLC lifted its stake in shares of Liquidia by 54.7% during the third quarter. Walleye Trading LLC now owns 13,201 shares of the company’s stock valued at $132,000 after buying an additional 4,670 shares during the period. D. E. Shaw & Co. Inc. acquired a new position in Liquidia during the fourth quarter worth approximately $142,000. Finally, EntryPoint Capital LLC acquired a new position in Liquidia during the fourth quarter worth approximately $154,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).